Cargando…

Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier

In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facilitated by delocalizing tight junction proteins such as cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvador, Ellaine, Köppl, Theresa, Hörmann, Julia, Schönhärl, Sebastian, Bugaeva, Polina, Kessler, Almuth F., Burek, Malgorzata, Ernestus, Ralf-Ingo, Löhr, Mario, Hagemann, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861254/
https://www.ncbi.nlm.nih.gov/pubmed/36678814
http://dx.doi.org/10.3390/pharmaceutics15010185
_version_ 1784874795493490688
author Salvador, Ellaine
Köppl, Theresa
Hörmann, Julia
Schönhärl, Sebastian
Bugaeva, Polina
Kessler, Almuth F.
Burek, Malgorzata
Ernestus, Ralf-Ingo
Löhr, Mario
Hagemann, Carsten
author_facet Salvador, Ellaine
Köppl, Theresa
Hörmann, Julia
Schönhärl, Sebastian
Bugaeva, Polina
Kessler, Almuth F.
Burek, Malgorzata
Ernestus, Ralf-Ingo
Löhr, Mario
Hagemann, Carsten
author_sort Salvador, Ellaine
collection PubMed
description In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facilitated by delocalizing tight junction proteins such as claudin-5 from the membrane to the cytoplasm. In investigating the possibility that the same effects could be observed in human-derived cells, a 3D co-culture model of the BBB was established consisting of primary microvascular brain endothelial cells (HBMVEC) and immortalized pericytes, both of human origin. The TTFields at a frequency of 100 kHz administered for 72 h increased the permeability of our human-derived BBB model. The integrity of the BBB had already recovered 48 h post-TTFields, which is earlier than that observed in cerebEND. The data presented herein validate the previously observed effects of TTFields in murine models. Moreover, due to the fact that human cell-based in vitro models more closely resemble patient-derived entities, our findings are highly relevant for pre-clinical studies.
format Online
Article
Text
id pubmed-9861254
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98612542023-01-22 Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier Salvador, Ellaine Köppl, Theresa Hörmann, Julia Schönhärl, Sebastian Bugaeva, Polina Kessler, Almuth F. Burek, Malgorzata Ernestus, Ralf-Ingo Löhr, Mario Hagemann, Carsten Pharmaceutics Article In a recent study, we showed in an in vitro murine cerebellar microvascular endothelial cell (cerebEND) model as well as in vivo in rats that Tumor-Treating Fields (TTFields) reversibly open the blood–brain barrier (BBB). This process is facilitated by delocalizing tight junction proteins such as claudin-5 from the membrane to the cytoplasm. In investigating the possibility that the same effects could be observed in human-derived cells, a 3D co-culture model of the BBB was established consisting of primary microvascular brain endothelial cells (HBMVEC) and immortalized pericytes, both of human origin. The TTFields at a frequency of 100 kHz administered for 72 h increased the permeability of our human-derived BBB model. The integrity of the BBB had already recovered 48 h post-TTFields, which is earlier than that observed in cerebEND. The data presented herein validate the previously observed effects of TTFields in murine models. Moreover, due to the fact that human cell-based in vitro models more closely resemble patient-derived entities, our findings are highly relevant for pre-clinical studies. MDPI 2023-01-04 /pmc/articles/PMC9861254/ /pubmed/36678814 http://dx.doi.org/10.3390/pharmaceutics15010185 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Salvador, Ellaine
Köppl, Theresa
Hörmann, Julia
Schönhärl, Sebastian
Bugaeva, Polina
Kessler, Almuth F.
Burek, Malgorzata
Ernestus, Ralf-Ingo
Löhr, Mario
Hagemann, Carsten
Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier
title Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier
title_full Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier
title_fullStr Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier
title_full_unstemmed Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier
title_short Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier
title_sort tumor treating fields (ttfields) induce cell junction alterations in a human 3d in vitro model of the blood-brain barrier
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861254/
https://www.ncbi.nlm.nih.gov/pubmed/36678814
http://dx.doi.org/10.3390/pharmaceutics15010185
work_keys_str_mv AT salvadorellaine tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier
AT koppltheresa tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier
AT hormannjulia tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier
AT schonharlsebastian tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier
AT bugaevapolina tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier
AT kessleralmuthf tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier
AT burekmalgorzata tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier
AT ernestusralfingo tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier
AT lohrmario tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier
AT hagemanncarsten tumortreatingfieldsttfieldsinducecelljunctionalterationsinahuman3dinvitromodelofthebloodbrainbarrier